Skip to main content

Identification of novel targets for cancer therapy

Objective

Despite intensive worldwide research efforts, cancer remains a devastating, often poorly treatable disease. We propose to develop and apply new functional genomics technologies that will provide unique approaches to the design of new pathway- specific cancer therapies. Our specific objectives are: 1)To develop large-scale functional genomic analysis to identify novel mechanisms involved in cancer development; specifically, we will generate the tools and technologies to carry out genome-wide loss-of-function screens in mammalian cells. 2)To apply these technologies to specific models of major human cancer-causing pathways to define novel targets for therapy. 3)To use existing and generate novel mouse models and non-invasive tumour imaging to validate and assay cancer gene function in vivo and to develop new treatment modalities. 4)To develop cell-based assays for cancer-relevant genes and pathways that will serve as readout for the identification of anticancer agents through the screening of chemical compound libraries. 5)To distribute and disseminate the novel technologies for the study of gene function in vitro and vivo within the consortium and to researchers in the European Community. To reach these objectives we have formed a multidisciplinary research consortium, including top scientists with extensive experience in developing innovative genomics technologies and with an excellent track-record in identifying key signalling molecules involved in cancer, as well as SMEs with experience in identifying cancer-relevant genes and in screening chemical compound libraries. The location of most of the partners at leading European cancer centers will ensure optimal conditions for the development of novel cancer-specific treatments. This proposal provides new possibilities of "Translating basic knowledge of functional oncogenomics into cancer diagnosis and treatment" in compliance with the main goal in the "LifeSciHealth" call in FP6.

Call for proposal

FP6-2002-LIFESCIHEALTH
See other projects for this call

Coordinator

UNIVERSITY OF COPENHAGEN
Address
Nørregade 10
2177 Copenhagen K
Denmark

Participants (12)

THE NETHERLANDS CANCER INSTITUTE / ANTONI VAN LEEUWENHOEK HOSPITAL
Netherlands
Address
Plesmanlaan 121
Amsterdam
CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS
Spain
Address
Sinesio Delgado, 6
Madrid
INSTITUT FÜR MIKROBIOLOGIE UND GENETIK - UNIVERSITÄT WIEN
Austria
Address
Dr. Bohr Gasse 9
Vienna
MAX-DELBRUECK-CENTER FOR MOLECULAR MEDICINE
Germany
Address
Robert-roessle-strasse 10
Berlin
UNIVERSITY OF MARBURG
Germany
Address
Biegenstr. 10
Marburg
SWISS INSTITUTE FOR EXPERIMENTAL CANCER RESEARCH
Switzerland
Address
Chemin Des Boveresses 155
Epalinges
BEATSON INSTITUTE FOR CANCER RESEARCH
United Kingdom
Address
Switchback Road
Bearsden, Glasgow
INSTITUT PASTEUR
France
Address
28 Rue Du Dr. Roux
Paris
MORPHOCHEM AG
Germany
Address
Gmunder Str. 37-37A
Munich
AGENDIA BV
Netherlands
Address
Slotervaart Medical Center 9D, Louwesweg 6
Amsterdam
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Italy
Address
Via Filodrammatici, 10
Milan
VICHEM CHEMIE RESEARCH LTD.
Hungary
Address
Hermann Ottó Street. 15
Budapest